UROLOGIX TARGIS MICROWAVE BPH THERAPY DEVICE TO LIST AT $150,000, FIRM SAYS; FDA APPROVAL CLEARS WAY FOR LAUNCH OF COMPETITION TO EDAP'S PROSTATRON
This article was originally published in The Gray Sheet
Executive Summary
Urologix is heating up competition in the benign prostatic hyperplasia microwave therapy market with the U.S. launch of its Targis system, which is slated for the fourth quarter of 1997. Urologix is the second company, after Edap Technomed, to gain approval for a microwave-based BPH therapy system.